Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Methylene blue.

Jack Clifton1, Jerrold B Leikin

  • 1Department of Pediatrics, Rush Medical College, Chicago, IL, USA.

American Journal of Therapeutics
|July 8, 2003
PubMed
Summary
This summary is machine-generated.

Methylene blue effectively treats methemoglobinemia by converting it back to hemoglobin. However, this drug carries risks, particularly dose-related hemolysis and potential dangers for individuals with G-6-PD deficiency or exposure to certain chemicals.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Changes in Exposures of US Children Ages 12 and Under to Cannabis from 2000 to 2024.

Journal of addiction medicine·2026
Same author

Foreword for Glucagon-like peptide-1 receptor agonists (GLP-1) and its promise for potential benefits.

Disease-a-month : DM·2026
Same author

Foreword for insulin autoimmune syndrome (Hirata Disease): An updated review of epidemiology, pathophysiology, clinical features, diagnosis, and management.

Disease-a-month : DM·2026
Same author

Foreword for primary ciliary dyskinesia in pediatric persons: A microscopic movement malady.

Disease-a-month : DM·2026
Same author

Foreword for periodontal disease and diabetic kidney disease: A comprehensive analysis.

Disease-a-month : DM·2026
Same author

Forward for: Approved weight loss drugs for obesity with a thorough emphasis on GLP-1 agonist medications: A systematic review.

Disease-a-month : DM·2026
Same journal

Deucravacitinib for Generalized Pustular Psoriasis and Comorbid Polymyositis: Dual Efficacy and Favorable Safety.

American journal of therapeutics·2026
Same journal

Repurposed Drugs and Cardiovascular Morbidity: A Cost-Effectiveness Analysis.

American journal of therapeutics·2026
Same journal

Do Not Treat a Sequencing Report: Therapeutic Stewardship in Endometrial Microbiome Testing.

American journal of therapeutics·2026
Same journal

Right Side Accessory Pathway Mediated Cardiomyopathy Treated with Amiodarone: First Adult Case Report.

American journal of therapeutics·2026
Same journal

Dose-Dependent Escitalopram-Induced Anejaculation and Anorgasmia: Rapid Reversal After Discontinuation and Bupropion Therapy.

American journal of therapeutics·2026
Same journal

Critical Appraisal of "Continued versus Interrupted Oral Anticoagulation During Transcatheter Aortic Valve Replacement in Patients with Atrial Fibrillation: A Meta-Analysis".

American journal of therapeutics·2026
See all related articles

Area of Science:

  • Toxicology
  • Pharmacology
  • Hematology

Background:

  • Methemoglobinemia is a condition where hemoglobin is oxidized, reducing oxygen transport.
  • Methylene blue is a primary treatment for methemoglobinemia.
  • Understanding methylene blue's mechanism and risks is crucial for safe clinical application.

Purpose of the Study:

  • To summarize the toxicological applications of methylene blue.
  • To detail the mechanism of action of methylene blue in treating methemoglobinemia.
  • To highlight potential risks and special considerations associated with methylene blue therapy.

Main Methods:

  • Literature review of methylene blue's use in toxicology.
  • Analysis of methylene blue's interaction with methemoglobin and erythrocyte enzymes.

Related Experiment Videos

  • Identification of patient populations at risk during methylene blue treatment.

    • Main Results:

    • Methylene blue is administered intravenously at 1 to 2 mg/kg for methemoglobinemia.
    • The drug facilitates the reduction of methemoglobin back to functional hemoglobin.
    • Dose-related hemolytic effects are observed, and specific patient groups face increased risks.

    Conclusions:

    • Methylene blue is a generally safe and effective antidote for methemoglobinemia.
    • Careful dosing and patient selection are necessary to mitigate risks like hemolysis.
    • Individuals with G-6-PD deficiency and those exposed to aniline dyes or dapsone require special attention.